Adma Biologics reported $71.95M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Adma Biologics USD 71.95M 7.75M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 126.2M 23.62M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Takeda JPY 981.78B 36.71B Sep/2026